

See, MPEP 803. All the claims of the present application are related, e.g., antibodies to ED-B domain of fibronectin. Consequently, a search would involve overlapping subject matter, and would not be an undue burden. On the other hand, the financial burden on Applicant is enormous - the prosecution of three separate patent applications is required, with a three-fold duplication of fees, costs, and time. Withdrawal of the restriction is therefore appropriate, or at the very least, the regrouping described above.

Respectfully submitted,

By: 

Richard M. Lebovitz (Reg. No. 37,067)
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201
Direct Dial: (703) 812-5317
Internet address: lebovitz@mwzb.com

Filed: September 1, 2000

RML:njr
K:\PAT\Sch\1733P1\response to restriction req 09.01.00.wpd